Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART

Ahmad R Sedaghat, Janet D Siliciano, Timothy P Brennan, Claus O Wilke, Robert F Siliciano, Ahmad R Sedaghat, Janet D Siliciano, Timothy P Brennan, Claus O Wilke, Robert F Siliciano

Abstract

Whereas cells productively infected with human immunodeficiency virus type 1 (HIV-1) decay rapidly in the setting of highly active antiretroviral therapy (HAART), latently infected resting CD4(+) T cells decay very slowly, persisting for the lifetime of the patient and thus forming a stable reservoir for HIV-1. It has been suggested that the stability of the latent reservoir is due to low-level viral replication that continuously replenishes the reservoir despite HAART. Here, we offer the first quantitative study to our knowledge of inflow of newly infected cells into the latent reservoir due to viral replication in the setting of HAART. We make use of a previous observation that in some patients on HAART, the residual viremia is dominated by a predominant plasma clone (PPC) of HIV-1 not found in the latent reservoir. The unique sequence of the PPC serves as a functional label for new entries into the reservoir. We employ a simple mathematical model for the dynamics of the latent reservoir to constrain the inflow rate to between 0 and as few as 70 cells per day. The magnitude of the maximum daily inflow rate is small compared to the size of the latent reservoir, and therefore any inflow that occurs in patients on HAART is unlikely to significantly influence the decay rate of the reservoir. These results suggest that the stability of the latent reservoir is unlikely to arise from ongoing replication during HAART. Thus, intensification of standard HAART regimens should have minimal effects on the decay of the latent reservoir.

Conflict of interest statement

Competing interests. The authors have declared that no competing interests exist.

Figures

Figure 1. PPCs Show Limited Entry into…
Figure 1. PPCs Show Limited Entry into Resting CD4+ T Cells of Patients on HAART
(A and B) Results are shown for two patients, pt. 148 (A) and pt. 154 (B). The heterogeneity of the latent reservoir in comparison to the homogeneity of the plasma virus in these patients is represented with pie charts in which distinct genotypes are indicated in different colors. The PPC for each patient is shown in red. Intensive sampling of the plasma virus was carried out by sampling three times per week over a 3- to 4-mo period as indicated by the thin vertical marks on the time line. For pt. 154, additional samples of plasma virus (small circles) were obtained before and on several occasions after the period of intensive sampling. These document the persistence of the PPC for a minimum of approximately 900 d. Sampling of proviruses in resting CD4+ T cells was carried out before and on multiple occasions after the period of intensive plasma sampling. With one exception (*), all of the cellular sequences remained distinct from the PPC. The numbers below each circle represent the number of independent sequences analyzed. For pt. 154, the plasma samples after study day 900 were analyzed by RT-PCR of the env gene. Previously, linkage studies [45] allowed us to identify the PPC in the env sequences. Phylogenetic analysis of these sequences is described in detail elsewhere [45].
Figure 2. Dynamics of the Latent Reservoir…
Figure 2. Dynamics of the Latent Reservoir (Black) L for the Three Described Regimes with Respect to the Steady State of L (Red) and a Purely Exponential Decay Defined by (Blue)
(A) Regime 1; koutL(t) ≫ kin. (B) Regime 2; koutL(t) = kin. (C) Regime 3; koutL(t) ≈ kin and koutL(t) > kin.

References

    1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188.
    1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300.
    1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284–1290.
    1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193–13197.
    1. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295.
    1. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–191.
    1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–517.
    1. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–728.
    1. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003;100:4819–4824.
    1. Davey RT, Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96:15109–15114.
    1. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 2005;115:3250–3255.
    1. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, Jr, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627–1632.
    1. Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol. 2003;77:5721–5730.
    1. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614–1622.
    1. Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis. 2001;183:36–50.
    1. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet. 1999;353:119–120.
    1. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol. 2005;79:9625–9634.
    1. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr. 2004;35:33–37.
    1. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82–85.
    1. Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001;286:196–207.
    1. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis. 2004;189:1452–1465.
    1. Pomerantz RJ. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Biomed Pharmacother. 2001;55:7–15.
    1. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:179–183.
    1. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–4536.
    1. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967–1969.
    1. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001;286:171–179.
    1. Mira JA, Macias J, Nogales C, Fernandez-Rivera J, Garcia-Garcia JA, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther. 2002;7:251–256.
    1. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: Discovery and clinical implications. J Antimicrob Chemother. 2004;54:6–9.
    1. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol. 2003;77:7383–7392.
    1. Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol. 2004;78:9105–9114.
    1. Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481–9492.
    1. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002;185:315–323.
    1. Hellerstein MK, McCune JM. T cell turnover in HIV-1 disease. Immunity. 1997;7:583–589.
    1. Hellerstein MK, Hoh RA, Hanley MB, Cesar D, Lee D, et al. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest. 2003;112:956–966.
    1. Neese RA, Misell LM, Turner S, Chu A, Kim J, et al. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A. 2002;99:15345–15350.
    1. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A. 1997;94:6971–6976.
    1. Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol. 1997;71:3275–3278.
    1. De Boer RJ, Perelson AS. Target cell limited and immune control models of HIV infection: a comparison. J Theor Biol. 1998;190:201–214.
    1. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat Med. 2002;8:319–323.
    1. Nowak MA, Bonhoeffer S, Shaw GM, May RM. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations. J Theor Biol. 1997;184:203–217.
    1. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582–1586.
    1. Perelson AS, Essunger P, Ho DD. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS. 1997;11(Suppl A):S17–S24.
    1. Phillips AN. Reduction of HIV concentration during acute infection: Independence from a specific immune response. Science. 1996;271:497–499.
    1. Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays. 2002;24:1178–1187.
    1. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441–6457.
    1. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817–829.
    1. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol. 2005;304:3–15.
    1. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med. 2001;194:1277–1287.
    1. Ribeiro RM, Mohri H, Ho DD, Perelson AS. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A. 2002;99:15572–15577.
    1. Ewens WJ, Grant G. Statistical methods in bioinformatics an introduction. New York: Springer; 2001. 476
    1. Orlitsky A, Santhanam NP, Zhang J. Always Good Turing: Asymptotically optimal probability estimation. Science. 2003;302:427–431.
    1. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605–1613.
    1. Simmons R, Siliciano RF. Can antiretroviral therapy ever be stopped? An update. AIDS Read. 2004;14:435–2.
    1. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: Pathogenesis and cardiovascular risk. Am J Ther. 2006;13:248–260.
    1. Manchanda T, Schiedel D, Fischer D, Dekaban GA, Rieder MJ. Adverse drug reactions to protease inhibitors. Can J Clin Pharmacol. 2002;9:137–146.
    1. Deeks SG. The risk of treatment versus the risk of HIV replication. Lancet. 2006;367:1955–1956.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir